Clinical Trial

Tolerance Through Mixed Chimerism (Sip-Tego)

Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This is an open-label, single-institution study to assess the safety and the efficacy of the Sip-Tego regimen for the induction of donor-specific immunologic unresponsiveness to a renal allograft. The investigators propose to treat 6 adult subjects in end-stage renal disease (ESRD) who do not demonstrate evidence of prior sensitization.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2025-05-07; most recent amendment 2026-07-21.
Status change: Not Yet Recruiting → Recruiting 2025-09-22
Trial Details
NCT Number NCT06972069
Lead Sponsor Tatsuo Kawai, MD, PhD
Collaborators: Eledon Pharmaceuticals, ITB-Med LLC
Conditions Kidney Failure, Transplant Recipient (Kidney), Transplant Tolerance, Immunosuppresion, Immunosuppression After Kidney Transplantation
Enrollment 12 participants
Start Date 2025-05-31
Primary Completion 2030-12-31 (estimated)
Study Completion 2030-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-22